Multiple attempts to obtain additional information were made with no response.The file for this donor was reviewed and met all criteria for allograft processing as well as medical director review.Therefore, the donor was found to be eligible for donation, and the tissue was released per all processing criteria.No tissue was returned for evaluation and no laboratory or pathology reports have been provided to confirm the reported endocarditis.The cardiac ifu lists endocarditis and microbial infection as a potential complication and should be considered in the decision of graft selection.Given the limited amount of information available, the source of the reported endocarditis cannot be determined.There is insufficient information to determine the root cause for the reported endocarditis or any relation to the allograft/donor.Adequate precautions are provided in the instructions for use.The viable grafts processed for this donor were found to have acceptable microbiological results and were approved for release.Given that all microbiological testing performed by artivion during processing produced acceptable results, the reported event most likely represents a contamination occurring at the implanting site.The current controls in place adequately mitigate risk to the patient.As such, no further action is required at this time.Risk has been reduced as low as possible and overall residual risk is acceptable this report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to artivion is accurate or has been confirmed by artivion.
|